Прогестерон: Main Uses and Key Symptomatic Benefits

Прогестерон (Progesterone) is applied across domains where additional symptomatic support is needed, assisting in managing symptoms related to hormonal status and reproductive health. The therapeutic use of this medication is relevant for managing certain conditions.

It is commonly used to help with symptomatic concerns in conditions involving episodic or fluctuating manifestations. It is often used when symptoms intensify and supportive relief is needed. In these clinical scenarios, the medication provides support that helps ease the overall symptom burden.

This support extends across conditions characterized by periods of heightened symptoms or those that interfere with daily functioning. By addressing symptom clusters that may become intense or disruptive, Прогестерон contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Supports functional stability

This medicinal support assists with maintaining functional stability when symptoms are more noticeable, helping patients cope more steadily with difficult episodes.

Regulatory References

1. NIH MedlinePlus Drug Information

The official regulatory profile for Progesterone strictly defines eligibility based on patient demographics and pre-existing medical conditions. Use is generally established for Adult Women, including those undergoing Assisted Reproductive Technology (ART) for early pregnancy support, as stated in official labeling. Conversely, use is contraindicated in several groups due to risks identified by regulatory authorities.

Eligibility Scope

Population	Eligibility Status (Regulatory Labeling)
Absolute Prohibition	Contraindicated in patients with active or historical thromboembolic disorders, severe liver disease, malignancy of the breast or genital organs, and undiagnosed vaginal bleeding.
Age-Related	Safety and effectiveness are not established in the pediatric population or in geriatric patients over 65 years of age.
Conditional Use	Patients with renal insufficiency, diabetes mellitus, a history of psychic depression, or conditions influenced by fluid retention require caution and close monitoring.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (absolute prohibition), Not Established (insufficient data), and Requires Caution/Close Supervision (restricted use).

Connection to the overall eligibility profile: These classifications categorize risk, reserving the medicine for the studied adult population and explicitly prohibiting its use in individuals with serious comorbidities like severe hepatic impairment. Outside of specific ART protocols, regulatory documents require discontinuation if pregnancy occurs.

Interactions with other Medicines and Products

This section describes documented interactions between Progesterone and other medicinal products, strictly based on official regulatory information concerning changes in drug concentration.

---

Interacting Drug Categories

Interactions with Progesterone are primarily based on the drug’s metabolism by the liver, which heavily involves the Cytochrome P450 3A4 (CYP3A4) enzyme system.

• CYP3A4 Enzyme Inhibitors: Coadministration with strong inhibitors of the CYP3A4 enzyme, such as ketoconazole, may significantly increase the plasma concentrations and bioavailability of Progesterone. Caution is advised when these medicines are used together.
• CYP3A4 Enzyme Inducers: Concomitant use with strong inducers of the CYP3A4 enzyme may decrease the plasma concentrations of Progesterone. This reduction in exposure could potentially affect the expected therapeutic response.

Clinical and Regulatory Constraints

Since inducers and inhibitors of the CYP3A4 enzyme can alter the levels of Progesterone, the official prescribing information requires specific attention to co-treatment.

When a known CYP3A4 inducer is added to or withdrawn from a patient's treatment regimen, the patient's pharmacological response should be monitored closely. Such monitoring is necessary because the fluctuating enzyme activity may necessitate adjustments to the hormone's dosage. This constraint reflects the need to manage the potential for decreased efficacy or increased exposure resulting from these pharmacokinetic interactions.

How Прогестерон works: Mechanism of Action

---

Steroid Receptor Agonism and Gene Transcription

Прогестерон exerts its primary action by functioning as an agonist that binds to the nuclear Progesterone Receptors ( PRA and PRB). This genomic mechanism modulates the transcription of specific genes in target tissues, such as the endometrium. This action induces the secretory phase and promotes sustained uterine smooth muscle quiescence.

---

Neurosteroid Action and GABA A Receptor Modulation

Acting as a neurosteroid, Прогестерон rapidly affects the Central Nervous System ( CNS) by acting as a positive allosteric modulator of the inhibitory GABA A receptor complex. This enhancement of the GABA-mediated inhibitory signal increases overall neuronal inhibition in the brain, resulting in observable sedative and hypnotic physiological effects stemming from reduced neuronal excitability.

---

Thermoregulation and Smooth Muscle Quiescence

The drug exerts a direct mechanism on the hypothalamic thermoregulatory center, causing a consistent post-ovulatory rise in Basal Body Temperature ( BBT). Simultaneously, it acts on the myometrium, reducing its excitability and promoting uterine smooth muscle quiescence. The mechanism of action defines the resulting biological effects across reproductive and central nervous systems.

The administration of Progesterone is strictly defined by regulatory documents, which specify the route, dose, frequency, and duration of use.

Administration Methods and Dosing Rules

Official instructions identify the three primary routes of administration:

• Oral: Capsules containing micronized progesterone are typically taken as a single daily dose, often at bedtime, to manage certain intended effects and due to food increasing bioavailability. Dosing commonly ranges from 100 mg to 400 mg per day, depending on the specific regimen and indication.
• Vaginal: Formulations like gels, inserts, or suppositories are administered directly into the vagina. Dosing varies significantly, for instance, from 100 mg two to three times daily for luteal support to cyclical use of 90 mg gel.
• Intramuscular (IM) Injection: A sterile solution in oil is administered via IM injection. A common regimen for certain conditions is 5 mg to 10 mg daily for six to eight consecutive days.

Administration Scope	Official Guidelines
Route of Administration	Oral, Intravaginal, Intramuscular
Dosing Schedule	Varies: e.g., 200 mg daily for 12 days/cycle, or 400 mg at bedtime for 10 days
Timing in Relation to Meals	Oral capsules are often specified to be taken at bedtime, as concomitant food ingestion may increase drug availability.
Missed-Dose Rules	If a dose is missed, regulatory information generally instructs to take the next scheduled dose at the usual time and not to double the dose.

Procedural Structure

The official protocol dictates a precise sequence: the appropriate dosage form and route must be selected and administered according to a specific frequency pattern (daily or cyclically). This structure ensures the correct amount of medicine is delivered according to the officially approved schedule and duration. Specialized instructions, such as time-of-day administration, are necessary to comply fully with the required treatment protocol.

Research Evidence Overview of Studies for Прогестерон (Progesterone)

This summary provides an overview of the research landscape for Progesterone, focusing on the types of studies conducted, the outcomes they measured, and areas where data are limited or results have varied. This information is purely descriptive of the research and does not offer clinical advice or make performance claims.

---

Evidence for Use in Pregnancy: Preterm Birth and Miscarriage

Research on preventing early delivery was studied in large-scale Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies primarily focused on pregnant women with risk factors, such as a history of prior spontaneous preterm birth or a short cervix. Measured findings were not consistent across all specific patient groups studied, and results have reported different outcomes in women with a short cervix.

Studies examining recurrent miscarriage have employed randomized controlled trial designs, exploring hard clinical outcomes, with the primary outcome studied being the measurement of the live birth rate. The reported findings varied across studies, and some trials reported no significant difference in the measured rate when compared to the control group.

---

Evidence for Use in Fertility and Hormonal Balance

Progesterone was evaluated in RCTs for its application as Luteal Phase Support following Assisted Reproductive Technology (ART), monitoring key outcomes like the clinical pregnancy rate and the live birth rate. Findings reported measured outcomes in the observed populations during this defined time interval. For endometrial health, Progesterone was studied for its use in postmenopausal women receiving estrogen therapy; research examined outcomes related to endometrial histology and thickness.

What remains uncertain is the full scope of longer-term follow-up data on the health of children exposed in utero, as data remain insufficient beyond early childhood. Furthermore, inconsistent findings were observed concerning the broad recurrent miscarriage population and across all risk groups for preterm birth.

Key Studies & References

1. Effects of vaginal progesterone and placebo on preterm birth and antenatal outcomes in women with singleton pregnancies and short cervix on ultrasound: a meta-analysis
2. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages (PROMISE trial)
3. The efficacy and safety of luteal phase support with progesterone following ovarian stimulation and intrauterine insemination: A systematic review and meta-analysis
4. Progestogens and endometrial protection (British Menopause Society consensus statement/guideline)

Common questions about Прогестерон (FAQ)

---

Q: What should I do if I miss a dose?

Official product information generally states that a missed dose may be taken as soon as it is realized. However, if the time is near for your next scheduled dose, the regulatory information specifies to skip the missed dose and resume your regular schedule. The labeling specifies that a double dose should not be taken to make up for a missed dose.

---

Q: What is the specific risk of blood clots with this drug?

Official regulatory documents indicate that taking Progesterone may be associated with an increased risk of serious blood clots, including deep vein thrombosis, pulmonary embolism, stroke, and heart attack. This risk is notably discussed in the context of Progesterone being used in combination with estrogen-containing medicines. Official product information instructs discontinuation of the medicine if a blood clot is suspected.

---

Q: Can I take Progesterone with an antibiotic like Ketoconazole?

Official prescribing information notes that medications like ketoconazole, which are strong inhibitors of the CYP3A4 enzyme system in the liver, can affect Progesterone levels. Taking both together may significantly increase the concentration of Progesterone in the bloodstream. Due to this potential interaction, official prescribing information requires close monitoring of the patient's response, which may necessitate a dosage change.

---

Q: What is the difference between oral and vaginal administration?

The way Progesterone is absorbed and metabolized differs significantly depending on whether it is taken by mouth (oral capsules) or administered vaginally (inserts or gels). Regulatory documents show that the oral route is often linked to higher levels of certain progesterone byproducts in the blood. Differences in absorption and metabolism between the two routes account for their use in different treatment regimens.

---

Q: Does Progesterone interact with grapefruit juice?

Official patient information for Progesterone (particularly the oral and injectable forms) indicates a potential interaction with grapefruit and grapefruit juice. Because grapefruit juice can inhibit the liver enzyme that breaks down Progesterone, consuming it may increase the level of the hormone in your blood. Regulatory documents state that patients should not significantly alter their consumption of grapefruit during therapy.

---

Q: How long does it take for Progesterone to start working?

Official regulatory documents describe how quickly the medication enters the bloodstream, known as the time to reach maximum concentration ( C max). For example, after an intramuscular injection, maximum levels are typically reached within about eight hours. In terms of functional results, clinical studies report that one expected effect, such as withdrawal bleeding, may occur two to three days after the final dose in a course of therapy.

---

Q: What are the symptoms of an allergic reaction to Progesterone?

Regulatory information specifically warns about the possibility of serious allergic (hypersensitivity) reactions, including a severe type called an anaphylactoid reaction. Symptoms can include hives, rash, itching, a fast heartbeat, or difficulty breathing. The medication is officially contraindicated (should not be used) if a patient has a known allergy to Progesterone or any of its components.

How to Store and Dispose of Progesterone

Official regulatory guidelines strictly define the conditions necessary for storing and handling Progesterone to maintain its stability and effectiveness.

Mandatory Storage and Handling

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C.
Prohibited Conditions	Do not refrigerate or freeze. Avoid excess heat.
Protection	Keep in the original container, which must be tightly closed, and protect from light and moisture.
Child Safety	Keep out of the reach of children.

Disposal Requirements

Unused or expired Progesterone must be disposed of according to local regulatory requirements to prevent environmental contamination. Do not flush the medication down the toilet or pour it into a drain unless explicitly instructed to do so by a governmental body, as this product should avoid release to the environment.